Ovid Therapeutics (1OT) AI Stock Analysis

Ovid Therapeutics

(Frankfurt:1OT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low Financial LeverageThe comparatively low debt burden gives Ovid more balance-sheet flexibility than a highly leveraged clinical-stage biotech. Although losses remain substantial, modest leverage limits interest and refinancing pressure and leaves more capacity to prioritize research, development, and financing decisions.

Negative Factors

Severe Revenue DeclineThe sharp revenue contraction materially weakens Ovid’s current operating base and demonstrates that reported revenue is not yet a stable source of scale. Sustained low revenue limits internal funding for clinical programs and increases reliance on partnerships, milestone receipts, or external capital.

Ovid Therapeutics (1OT) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 496.06M
Dividend Yield: ―
Average Volume (3M): 50
Price to Earnings (P/E): -5.3
Beta (1Y): 1.18
Revenue Growth: -76.89%
EPS Growth: 56.40%
Country: Germany
Employees: 23
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Ovid Therapeutics Business Overview & Revenue Model

Company Description

Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic c...

Ovid Therapeutics Risk Analysis

Ovid Therapeutics disclosed 58 risk factors in its most recent earnings report. Ovid Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.Social media platforms and artificial intelligence-based platforms present new risks and challenges to our business.Q2, 2026

Ovid Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1OT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IRD	55Neutral	$305.33M	-2.89	1147.63%	―	-36.09%	24.84%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRZN	49Neutral	$341.32M	-0.71	187.62%	―	-8.79%	-195.46%
IKT	46Neutral	$216.28M	-3.26	-42.80%	―	―	59.89%
BMEA	44Neutral	$46.35M	-1.29	-171.19%	―	―	83.55%
ZNTL	40Underperform	$185.56M	-0.80	-87.95%	―	-100.00%	14.08%

* Healthcare Sector Average

Performance Comparison

DE:1OT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1OT	Ovid Therapeutics	2.24	1.08	93.10%
IRD	Opus Genetics, Inc.	3.67	1.53	71.50%
ZNTL	Zentalis Pharmaceuticals Inc	1.96	0.52	36.11%
IKT	Inhibikase Therapeutics, Inc.	1.55	-0.05	-3.13%
SRZN	Surrozen, Inc.	29.04	15.98	122.36%
BMEA	Biomea Fusion Inc	0.64	-0.68	-51.59%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Ovid Therapeutics AI Stock Analysis